Results 101 to 110 of about 10,193 (191)

LANGERHANS CELL HISTIOCYTOSIS

, 2005
Ulcerated nodules are often seen in the flexural areas of patients with Langerhans cell histiocytosis, or histiocytosis X (2,5-7). Infants with this condition have widespread cutaneous disease with a seborrheic rash involving the scalp and flexural ...

core   +1 more source

A 50‐year‐old man with a 12‐year history of extensive pachymeningeal thickening

Brain Pathology, Volume 36, Issue 4, July 2026.
Alyssa M. Lee, Siddhartha Gaddamanugu, Kathyrn L. Eschbacher, Aishwarya Ravindran   +3 more
wiley   +1 more source

Langerhans cell histiocytosis; an institutional study

, 2017
Background: Langerhans cell histiocytosis is a complex rare disease of the dendritic cell system.The disease can occur at any age, with a peak at 5-10 years.
Shovana Karki, Aasia Rajbhandari
core   +1 more source

Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis. [PDF]

Neurology, 2021
Francis JH, Gobin YP, Alshiekh Nasany R, Knopman J, Ulaner GA, Panageas KS, Hatzoglou V, Salvaggio K, Abramson DH, Patsalides A, Diamond EL.   +10 more
europepmc   +1 more source

Fear of Progression in Pediatric Cancer Patients and Their Parents: Trajectories, Prevalence, and Correlates Across Acute Treatment and Follow‐Up Care

Psycho-Oncology, Volume 35, Issue 6, June 2026.
ABSTRACT Purpose Fear of progression (FoP) represents a significant psychological burden for pediatric cancer patients and their parents. This study investigates FoP levels across acute treatment (AcT) and follow‐up care (FuC) and examines trajectories over time, associated sociodemographic factors, and parent‐child associations.
Jessy Herrmann, Kristina Herzog, Julia Martini, Anja Santel, Leonard Konstantin Kulisch, Jörn‐Sven Kühl, Florian Schepper   +6 more
wiley   +1 more source

Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study

International Journal of Cancer, Volume 158, Issue 10, Page 2674-2683, 15 May 2026.
What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Xue Tang, Jing‐jing Sun, Zhi Wan, Xiao‐yu Jing, Xia Guo, Ju Gao   +5 more
wiley   +1 more source

Endocrine manifestations in Langerhans cell histiocytosis.

, 2007
Langerhans cell histiocytosis is a rare, multisystem disease that shows a particular predilection for hypothalamo-pituitary axis involvement. Diabetes insipidus is the most frequent permanent consequence of Langerhans cell histiocytosis, developing in ...
Chrousos, GP, Grossman, AB, Kaltsas, GA, Makras, P, Alexandraki, KI   +4 more
core   +2 more sources

Pulmonary Langerhans' cell histiocytosis (histiocytosis X) following metastasising malignant melanoma

, 2002
Background: Pulmonary Langerhans' cell histiocytosis (histiocytosis X) is an uncommon, diffuse interstitial lung disease of unknown cause, mostly presenting in young smokers.
Mirzaie, Masoud, Tirilomis, Theodor, Dalichau, H., Zenker, Dieter   +3 more
core  

Adult langerhans cell histiocytosis

, 2007
Langerhans cell histiocytosis is a group of idiopathic disorders characterized by the abnormal proliferation of specialized bone marrow-derived Langerhans cells. There are one to two cases per million population.
Bahceci, Mithat, Goekalp, Deniz, Tuzcu, Alparslan, Isikdogan, Abdurrahman, Cil, Timucin   +4 more
core  

Langerhans cell histiocytosis of the thyroid mimicking thyroiditis in a boy: a case report and literature review

BMC Pediatrics
Background Langerhans cell histiocytosis affecting the thyroid commonly presents with nonspecific clinical and radiological manifestations. Thyroid Langerhans cell histiocytosis is typically characterized by non-enhancing hypodense lesions with an ...
Yu Fan Cheng, Ching Che Wang, Pei Shan Tsai, Dao Chen Lin, Wen Hui Huang   +4 more
doaj   +1 more source